CN112168885A - Compound essential oil for treating insomnia - Google Patents

Compound essential oil for treating insomnia Download PDF

Info

Publication number
CN112168885A
CN112168885A CN202011016359.XA CN202011016359A CN112168885A CN 112168885 A CN112168885 A CN 112168885A CN 202011016359 A CN202011016359 A CN 202011016359A CN 112168885 A CN112168885 A CN 112168885A
Authority
CN
China
Prior art keywords
essential oil
oil
compound
essential
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011016359.XA
Other languages
Chinese (zh)
Inventor
潘祎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuyuetang Education Technology Beijing Co ltd
Original Assignee
Wuyuetang Education Technology Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuyuetang Education Technology Beijing Co ltd filed Critical Wuyuetang Education Technology Beijing Co ltd
Priority to CN202011016359.XA priority Critical patent/CN112168885A/en
Publication of CN112168885A publication Critical patent/CN112168885A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The embodiment of the invention discloses compound essential oil for treating insomnia, belonging to the technical field of medicines. The compound essential oil is compounded by plant essential oil and base oil, the adopted raw materials are all pure natural substances, and the compound essential oil can be naturally discharged through body fluid metabolism after being used, and has small side effect. Clinical tests prove that the traditional Chinese medicine composition has a remarkable improvement effect on insomnia caused by deficiency of heart and spleen, deficiency of heart and gallbladder qi, disharmony between heart and kidney, liver depression transforming into fire and phlegm heat internal disturbance, can improve the sleep quality of patients, and is worthy of clinical popularization and application.

Description

Compound essential oil for treating insomnia
Technical Field
The embodiment of the invention relates to the technical field of medicines, and particularly relates to compound essential oil for treating insomnia.
Background
Sleep problems are a common problem in modern society, 45.4% of people in China experience different degrees of insomnia in the past month, which is much higher than the average level in other countries and the world, and the insomnia symptom duration of 53% and even higher proportion of people is more than 1 year. On the public level, the attention degree to the insomnia problem is seriously insufficient, people who are nearly five-fold do not take any measures, and many people use own modes to solve the problem without advice, such as: drinking wine, taking hypnotics, etc. Not only the insomnia problem can not be relieved, but also a vicious circle can be formed, and more serious neurological diseases can be caused.
There are many reasons for insomnia clinically, including mental factors, environmental factors, physical diseases, pharmaceutical factors, lifestyle habits, age factors, and the like. Patients often have three forms of difficult falling asleep, uneasy sleep and early waking, and sometimes can have symptoms of dreaminess, dizziness, hypodynamia and the like.
Chronic insomnia can cause many neurological, psychiatric and sub-health symptoms. Such as dysphoria, depression, alertness, decreased mobility, autonomic dysfunction, digestive dysfunction, etc., and even lowering immune function, affecting health and working efficiency, and reducing life quality.
At present, the main modes for treating insomnia include drug treatment and psychological intervention.
1. Medical treatment
Benzodiazepine receptor antagonists
The benzodiazepine medicine is the hypnotic which is most widely applied at present, can shorten the time of falling asleep, reduce the time and frequency of awakening and increase the total sleep time, and is the hypnotic with better safety and tolerance. Commonly used drugs include triazolam, midazolam, lorazepam, alprazolam, estazolam, and the like.
Melatonin receptor agonists
Melatonin receptor agonists can be used as substitute therapy for the intolerance and drug-dependent response of benzodiazepine receptor antagonists, and the commonly used drugs include agomelatine and ramelteon.
Antidepressant drug
Is mainly used for treating patients who have long-term insomnia and are accompanied with depression and anxiety. Commonly used drugs are doxepin, mirtazapine, trazodone and the like. Wherein the imidazolone has sedative effect, and can be used for treating insomnia and insomnia rebound after hypnotic.
The disadvantages of drug therapy include easy drug dependence, drug withdrawal rebound and memory deterioration, and is not suitable for children, pregnant and lying-in women, etc.
2. Psychological intervention
Sleep Cognitive Behavioral Therapy (CBT)
The method is effective for treating sleep disorder, and doctors can promote sleep by changing the opinions of patients on sleep, adjusting sleep habits and the like.
Psychological adjustment method
The doctor will make the patient realize that sleep is a natural reaction of the body, following the nature, and not have to control it deliberately.
The psychological intervention has the disadvantages of long time period, obvious fluctuation of the effect due to treatment schemes and individual differences, and indefinite effect.
3. Physical therapy
The insomnia intervention including transcranial magnetic stimulation and biofeedback treatment is performed through instruments and equipment, the cost is high, and the single treatment time is long.
The product uses aromatic substances extracted from pure plants, has the functions of relieving pressure, helping sleep and improving sleep, has no toxic or side effect on human bodies, and can be used by wide crowds for a long time.
Disclosure of Invention
Therefore, the embodiment of the invention provides the compound essential oil for treating insomnia, which is used for solving the problems of great side effect and insignificant curative effect in the prior art.
In order to achieve the above object, the embodiments of the present invention provide the following technical solutions:
according to a first aspect of the embodiments of the invention, the compound essential oil for treating heart-spleen deficiency type insomnia is prepared by compounding plant essential oil and base oil, and comprises, by weight, 0.5-1% of marjoram essential oil, 0.5-1% of sweet orange essential oil, 0.5-1% of roman chamomile essential oil, 1-1.5% of orange flower essential oil, 1.5-2% of striking lavender essential oil, 2-2.5% of bitter orange leaf essential oil, 2-2.5% of pine essential oil, and the balance of base oil.
In view of safety in mass popularization, preferably, the compound essential oil comprises, in percentage by weight, 0.5% of marjoram essential oil, 0.5% of sweet orange essential oil, 0.5% of roman chamomile essential oil, 1% of orange flower essential oil, 1.5% of eye-catching lavender essential oil, 2% of bitter orange leaf essential oil, 2% of pine essential oil, and the balance of base oil.
For patients with more serious symptoms, the concentration can be correspondingly increased according to the situation, the effect is better, and preferably, the compound essential oil comprises 1% of marjoram essential oil, 1% of sweet orange essential oil, 1% of Roman chamomile essential oil, 1.5% of orange flower essential oil, 2% of striking lavender essential oil, 2.5% of bitter orange leaf essential oil, 2.5% of pine essential oil and the balance of base oil in percentage by weight.
Preferably, the base oil is one or more selected from wheat germ oil, jojoba oil, avocado oil, sweet almond oil and grape seed oil. The base oil is extracted from pure plants, is diluted and blended as a carrier, and plays roles in lubricating skin, diluting concentration, preventing corrosion and preserving freshness.
According to a second aspect of the embodiment of the invention, the compound essential oil for treating insomnia caused by deficiency of heart-qi and gallbladder-qi is prepared by compounding plant essential oil and base oil, and comprises, by weight, 2-2.5% of magnolia alba leaf essential oil, 1-1.5% of rosewort essential oil, 0.5-1% of rosewood essential oil, 0.5-1% of tangerine essential oil, 2-2.5% of lime essential oil, 1-1.5% of valerian essential oil, 1-1.5% of ginger essential oil, and the balance of base oil.
In consideration of the safety of the general public, the compound essential oil preferably comprises, by weight, 2% of yulan magnolia leaf essential oil, 1% of rose essential oil, 0.5% of rosewood essential oil, 0.5% of tangerine essential oil, 2% of lime essential oil, 1% of valerian essential oil, 1% of ginger essential oil, and the balance of base oil.
For patients with more serious symptoms, the concentration can be correspondingly increased according to the conditions, the effect is better, and preferably, the compound essential oil comprises 2.5 percent of white magnolia leaf essential oil, 1.5 percent of rose essential oil, 1 percent of rosewood essential oil, 1 percent of tangerine essential oil, 2.5 percent of lime essential oil, 1.5 percent of valerian essential oil, 1.5 percent of ginger essential oil and the balance of base oil by weight percentage.
The base oil is selected from one or more of wheat germ oil, jojoba oil, avocado oil, sweet almond oil, and grape seed oil. The base oil is extracted from pure plants, is diluted and blended as a carrier, and plays roles in lubricating skin, diluting concentration, preventing corrosion and preserving freshness.
According to a third aspect of the embodiment of the invention, the compound essential oil for treating heart-kidney imbalance type insomnia is prepared by compounding plant essential oil and base oil, and comprises, by weight, 2-2.5% of roman chamomile essential oil, 1-1.5% of real lavender essential oil, 2-2.5% of tuberose essential oil, 1-1.5% of pink lotus flower essential oil, 0.5-1% of cypress essential oil, 1-1.5% of melissa essential oil, 0.5-1% of ginger essential oil and the balance of base oil.
In view of safety in mass popularization, the compound essential oil preferably comprises 2% of roman chamomile essential oil, 1% of real lavender essential oil, 2% of tuberose essential oil, 1% of pink lotus essential oil, 0.5% of cypress essential oil, 1% of melissa essential oil, 0.5% of ginger essential oil and the balance of base oil in percentage by weight.
For patients with more serious symptoms, the concentration can be correspondingly increased according to the situation, the effect is better, preferably, the compound essential oil comprises 2.5 percent of Roman chamomile essential oil, 1.5 percent of real lavender essential oil, 2.5 percent of tuberose essential oil, 1.5 percent of pink lotus essential oil, 1 percent of cypress essential oil, 1.5 percent of melissa essential oil, 1 percent of ginger essential oil and the balance of base oil in percentage by weight.
The base oil is selected from one or more of wheat germ oil, jojoba oil, avocado oil, sweet almond oil, and grape seed oil. The base oil is extracted from pure plants, is diluted and blended as a carrier, and plays roles in lubricating skin, diluting concentration, preventing corrosion and preserving freshness.
According to a fourth aspect of the embodiment of the invention, the compound essential oil for treating insomnia caused by liver depression transforming into fire is prepared by compounding plant essential oil and base oil, wherein the compound essential oil comprises, by weight, 0.5-1% of marjoram essential oil, 0.5-1% of vetiver essential oil, 1-1.5% of tangerine essential oil, 1-1.5% of spikenard essential oil, 2-2.5% of melissa officinalis essential oil, 2-2.5% of bergamot essential oil, 1-1.5% of german chamomile essential oil, and the balance of base oil.
In view of the safety spread by the public, preferably, the compound essential oil comprises, in weight percentage, 0.5% of marjoram essential oil, 0.5% of vetiver essential oil, 1% of tangerine essential oil, 1% of spikenard essential oil, 2% of melissa essential oil, 2% of bergamot essential oil, 1% of german chamomile essential oil, and the balance of base oil.
For patients with more serious symptoms, the concentration can be correspondingly increased according to the situation, the effect is better, and preferably, the compound essential oil comprises, by weight, 1% of marjoram essential oil, 1% of vetiver essential oil, 1.5% of tangerine essential oil, 1.5% of spikenard essential oil, 2.5% of balm essential oil, 2.5% of bergamot essential oil, 1.5% of german chamomile essential oil and the balance of base oil.
The base oil is selected from one or more of wheat germ oil, jojoba oil, avocado oil, sweet almond oil, and grape seed oil. The base oil is extracted from pure plants, is diluted and blended as a carrier, and plays roles in lubricating skin, diluting concentration, preventing corrosion and preserving freshness.
According to a fifth aspect of the embodiment of the invention, the compound essential oil for treating phlegm-heat internal disturbance type insomnia is prepared by compounding plant essential oil and base oil, and comprises, by weight, 2-2.5% of tangerine essential oil, 1-1.5% of sanshool essential oil, 2-2.5% of eucalyptol and rosemary essential oil, 1-1.5% of gardenia essential oil, 1-1.5% of ginger essential oil, 1-1.5% of valerian essential oil, and the balance of base oil.
In consideration of the safety of the popularization of the public, the compound essential oil preferably comprises 2% of tangerine essential oil, 1% of litsea cubeba essential oil, 2% of eucalyptol and rosemary essential oil, 1% of gardenia essential oil, 1% of ginger essential oil, 1% of valerian essential oil and the balance of base oil in percentage by weight.
For patients with more serious symptoms, the concentration can be correspondingly increased according to the conditions, the effect is better, and preferably, the compound essential oil comprises 2.5 percent of tangerine essential oil, 1.5 percent of litsea cubeba essential oil, 2.5 percent of eucalyptol and rosemary essential oil, 1.5 percent of gardenia essential oil, 1.5 percent of ginger essential oil, 1.5 percent of valerian essential oil and the balance of base oil in percentage by weight.
The base oil is selected from one or more of wheat germ oil, jojoba oil, avocado oil, sweet almond oil, and grape seed oil. The base oil is extracted from pure plants, is diluted and blended as a carrier, and plays roles in lubricating skin, diluting concentration, preventing corrosion and preserving freshness.
The preparation method of the compound essential oil comprises the following steps: mixing the components according to the weight ratio, and uniformly stirring to obtain the product.
The embodiment of the invention has the following advantages:
the compound essential oil for treating heart-spleen deficiency type insomnia provided by the invention takes marjoram, sweet orange, Roman chamomile, orange flower, striking lavender, bitter orange leaf and pine as effective components. Wherein the marjoram is used for resisting anxiety, palpitation, insomnia and neuralgia caused by autonomic nerve imbalance; sweet orange can regulate qi and dissipate stagnation, so that the smell is more pleasant; the Roman chamomile soothes the central nervous system, smoothes the mood of anxiety disorder, soothes and calms, and helps sleep; neroli treats stress and anxiety accumulated for a long time, and appeals the mood in the stagnation heart; improving insomnia caused by yin deficiency by improving lavender; bitter orange leaf can resist depression, make people happy and confident, and soothe and calm nervous system; pine strengthens nerves, and reinjects energy and courage for soul and body suffering from pressure-induced distress.
The compound essential oil for treating insomnia caused by deficiency of heart-qi and gallbladder-qi provided by the invention takes magnolia alba leaves, roselle, rosewood, tangerine, lime, valerian and ginger as effective components. Wherein, the magnolia denudata leaves tonify qi and soothe the nerves; the rose is used for tonifying the body and nerves, and the disordered emotion in work is relieved; the rosewood has the effects of nourishing heart qi, soothing the heart and bringing support feeling; the tangerine is capable of regulating qi and reducing phlegm, and is warm, sweet and sleep-aiding; lyme soothes liver and regulates qi, and relieves panic and worry symptoms caused by gallbladder qi deficiency; valerian root has the functions of tranquilizing and allaying excitement and resisting stress; the ginger is warm and motivated, and the safety feeling is enhanced.
The compound essential oil for treating heart-kidney imbalance type insomnia provided by the invention takes Roman chamomile, real lavender, tuberose, pink lotus flower, cypress, melissa officinalis and ginger as effective components. Wherein, the Roman chamomile has the effects of nourishing yin, clearing deficient fire, calming the nerves and calming the mind, and helping sleep; the lavender can nourish yin and soothe the liver, and improve insomnia caused by yin deficiency; the tuberose has the effects of nourishing kidney yin, improving symptoms such as palpitation and chest distress and the like, and helping sleep; the pink lotus flower can clear deficiency heat, moisten dryness, relieve restlessness, calm and calm the nerves; the cypress has the effect of guiding the channels, so that the force of the essential oil is guided into the kidney channels to help the heart and kidney to communicate; balm has effects of nourishing heart yin, dispersing stagnated liver qi, promoting bile flow, tranquilizing mind, and improving sleep; the ginger can play a role in regulating yin in yang, and a small amount of yang-tonifying essential oil is introduced into a large amount of yin-nourishing essential oil, so that the effect of the large amount of yin-nourishing essential oil on preventing the spleen and stomach transportation and transformation functions can be prevented.
The compound essential oil for treating liver depression forming fire type insomnia provided by the invention takes marjoram, vetiver, tangerine, spikenard, balm, bergamot and German sweet chrysanthemum as effective components. Wherein the marjoram relieves stress, resists anxiety caused by autonomic imbalance, and helps sleep; vetiver grass can clear stagnated heat in liver channel, and tranquilize mind; the tangerine peel warms, promotes vibration and clears qi, is used together with the vetiver, and has proper compatibility; the spikenard can nourish liver yin, suppress liver wind, calm mind and calm nerves; melissa officinalis has effects of soothing liver, promoting bile flow, improving stagnation of qi due to depression of liver, and stagnation of gallbladder channel, tranquilizing mind, and improving sleep; the bergamot can soothe the liver, relieve depression, regulate qi and harmonize middle warmer, and relieve emotional stress; german blue chamomile clears away stagnated heat generated by liver depression transforming into fire.
The compound essential oil for treating phlegm-heat internal disturbance type insomnia provided by the invention takes tangerine, litsea cubeba, eucalyptol, rosemary, gardenia, ginger and valerian as effective components. Wherein the tangerine peel can resolve phlegm and dampness, recover the functions of intestines and stomach and help sleep; the litsea cubeba regulates qi and relieves depression, soothes liver and benefits gallbladder, and improves symptoms such as bitter taste and dyspepsia; eucalyptol and rosemary can resolve phlegm and clear heat, and relieve the stomach and the intestine, and relieve the sleep; cape jasmine flower has the effects of purging fire, relieving restlessness, clearing heat and promoting diuresis; the ginger can achieve yin elimination in yang, and a small amount of warm essential oil is added into a large amount of heat-clearing and phlegm-eliminating essential oil, so that the phlegm-eliminating effect can be enhanced, and the cold and cold injury of the heat-clearing essential oil to the spleen and stomach can be prevented; valerian root has the functions of tranquilizing and allaying excitement and helping sleep.
The compound essential oil is absorbed into human body through respiratory tract or skin through various ways such as inhalation, massage, bath, incense, external application, etc., so as to achieve the effects of creating pleasant atmosphere, relieving mental stress, tranquilizing, improving sleep, balancing nerve center, and improving sleep disorder. In the invention, the insomnia types are divided into five types from the perspective of overall conditioning of the traditional Chinese medicine, so that the formula is used for symptomatic 'medicine administration' aiming at different types of insomnia.
The compound essential oil is compounded by plant essential oil and base oil, the adopted raw materials are all pure natural substances, and the compound essential oil can be naturally discharged through body fluid metabolism after being used, and has small side effect. Clinical tests prove that the traditional Chinese medicine composition has a remarkable improvement effect on insomnia caused by deficiency of heart and spleen, deficiency of heart and gallbladder qi, disharmony between heart and kidney, liver depression transforming into fire and phlegm heat internal disturbance, can improve the sleep quality of patients, and is worthy of clinical popularization and application.
Detailed Description
The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. In the following examples, "%" means weight percent, unless otherwise specified.
Example 1
The compound essential oil for treating heart-spleen deficiency type insomnia comprises 0.5% of marjoram essential oil, 0.5% of sweet orange essential oil, 0.5% of roman chamomile essential oil, 1% of orange flower essential oil, 1.5% of eye-catching lavender essential oil, 2% of bitter orange leaf essential oil, 2% of pine essential oil, 1% of wheat germ oil, 3% of jojoba oil, 5% of avocado oil, 20% of sweet almond oil and 63% of grape seed oil.
Example 2
The compound essential oil for treating heart-spleen deficiency type insomnia comprises 1% of marjoram essential oil, 1% of sweet orange essential oil, 1% of roman chamomile essential oil, 1.5% of orange flower essential oil, 2% of striking lavender essential oil, 2.5% of bitter orange leaf essential oil, 2.5% of pine essential oil, 0.5% of wheat germ oil, 2.5% of jojoba oil, 4.5% of avocado oil, 18% of sweet almond and 63% of grape seed oil.
Example 3
The compound essential oil for treating insomnia caused by deficiency of heart-qi and gallbladder-qi comprises 2% of white magnolia leaf essential oil, 1% of rose essential oil, 0.5% of rosewood essential oil, 0.5% of tangerine essential oil, 2% of lime essential oil, 1% of valerian essential oil, 1% of ginger essential oil, 1% of wheat germ oil, 3% of jojoba oil, 5% of avocado oil, 20% of sweet almond oil and 63% of grape seed oil.
Example 4
The compound essential oil for treating insomnia caused by deficiency of heart-qi and gallbladder-qi comprises 2.5% of white magnolia leaf essential oil, 1.5% of rose essential oil, 1% of rosewood essential oil, 1% of tangerine essential oil, 2.5% of lime essential oil, 1.5% of valerian essential oil, 1.5% of ginger essential oil, 0.5% of wheat germ oil, 2.5% of jojoba oil, 4.5% of avocado oil, 18% of sweet almond and 63% of grape seed oil.
Example 5
The compound essential oil for treating heart-kidney imbalance type insomnia comprises 2% of roman chamomile essential oil, 1% of real lavender essential oil, 2% of tuberose essential oil, 1% of pink lotus essential oil, 0.5% of cypress essential oil, 1% of melissa essential oil, 0.5% of ginger essential oil, 1% of wheat germ oil, 3% of jojoba oil, 5% of avocado oil, 20% of sweet almond oil and 63% of grape seed oil.
Example 6
The compound essential oil for treating heart-kidney imbalance type insomnia comprises 2.5% of Roman chamomile essential oil, 1.5% of real lavender essential oil, 2.5% of tuberose essential oil, 1.5% of pink lotus essential oil, 1% of cypress essential oil, 1.5% of melissa essential oil, 1% of ginger essential oil, 0.5% of wheat germ oil, 2.5% of jojoba oil, 4.5% of avocado oil, 18% of sweet almond and 63% of grape seed oil.
Example 7
The compound essential oil for treating liver depression forming fire type insomnia comprises 0.5% of marjoram essential oil, 0.5% of vetiver essential oil, 1% of tangerine essential oil, 1% of spikenard essential oil, 2% of melissa officinalis essential oil, 2% of bergamot essential oil, 1% of german blue chamomile essential oil, 1% of wheat germ oil, 3% of jojoba oil, 5% of avocado oil, 20% of sweet almond oil and 63% of grape seed oil.
Example 8
The compound essential oil for treating liver depression forming fire type insomnia comprises 1% of marjoram essential oil, 1% of vetiver essential oil, 1.5% of tangerine essential oil, 1.5% of spikenard essential oil, 2.5% of melissa officinalis essential oil, 2.5% of bergamot essential oil, 1.5% of german blue chamomile essential oil, 1% of wheat germ oil, 2.5% of jojoba oil, 5% of avocado oil, 20% of sweet almond oil and 60% of grape seed oil.
Example 9
The compound essential oil for treating phlegm-heat internal disturbance type insomnia comprises 2% of tangerine essential oil, 1% of sanshool essential oil, 2% of eucalyptol and rosemary essential oil, 1% of gardenia essential oil, 1% of ginger essential oil, 1% of valerian essential oil, 1.5% of wheat germ oil, 2.5% of jojoba oil, 4% of avocado oil, 20% of sweet almond and 64% of grape seed oil.
Example 10
The compound essential oil for treating phlegm-heat internal disturbance type insomnia comprises 2.5% of tangerine essential oil, 1.5% of sanshool essential oil, 2.5% of eucalyptol and rosemary essential oil, 1.5% of gardenia essential oil, 1.5% of ginger essential oil, 1.5% of valerian essential oil, 0.5% of wheat germ oil, 3% of jojoba oil, 4.5% of avocado oil, 18% of sweet almond and 63% of grape seed oil.
Test example 1
In order to show that the compound essential oil of the embodiment of the invention has the effect of treating insomnia, the invention carries out the following clinical tests.
1. General data
600 patients with insomnia who voluntarily participated in the study were selected as study subjects.
Among them, 120 cases of insomnia patients with heart-spleen deficiency syndrome, age 38-60, 48 cases of men, 72 cases of women, 36 cases of mild disease, 52 cases of moderate disease and 32 cases of severe disease. Inclusion criteria were: according with the diagnosis standard of traditional Chinese medicine (insomnia, easy wakening, dizziness, thin and white tongue coating and easy sweating).
120 cases of insomnia patients with deficiency of heart-qi and gallbladder-qi, age 35-65 years, 60 cases of men, 60 cases of women, 46 cases of mild disease, 22 cases of moderate disease and 38 cases of severe disease. Inclusion criteria were: meets the diagnosis standard of traditional Chinese medicine (palpitation, timidity, high fear, dreaminess and easy fright).
120 patients with heart-kidney imbalance type insomnia have age of 30-60, 65 men, 55 women, 24 patients with mild disease, 49 patients with moderate disease and 47 patients with severe disease. Inclusion criteria were: according with the diagnosis standard of traditional Chinese medicine (vexation and insomnia, or awakening when sleepy, feverish palms and soles, dizziness and tinnitus, palpitation, amnesia, flushed cheeks and tidal fever).
The number of patients with insomnia caused by liver depression transforming into fire is 120, the patients are 25-52 years old, 53 in men, 67 in women, 30 in mild disease, 48 in moderate disease and 42 in severe disease. Inclusion criteria were: meets the diagnosis standard of traditional Chinese medicine (vexation can not fall asleep, dysphoria and irritability, chest distress and hypochondriac pain, headache and dizziness, red face and eyes, bitter taste in mouth, constipation and yellow urine).
The phlegm-heat internal disturbance type insomnia patients have 120 cases, the age is 40-55 years old, 58 cases are male, 62 cases are female, the disease condition is 30 cases mildly, 40 cases moderately and 50 cases heavily. Inclusion criteria were: meets the diagnosis standard of traditional Chinese medicine (uncomfortable sleep, chagrin, stuffiness and stuffiness in the chest and epigastrium, bitter taste in mouth, excessive phlegm, dizziness and blurred vision).
2. Method of producing a composite material
The compound essential oil of example 1 is used for patients with mild and moderate insomnia caused by deficiency of heart and spleen; the compound essential oil of the example 2 is used by patients with severe insomnia caused by deficiency of both heart and spleen;
the compound essential oil of the example 3 is used for patients with mild and moderate insomnia caused by deficiency of heart-qi and gallbladder-qi; the compound essential oil of the example 4 is used by patients with severe insomnia caused by deficiency of heart-qi and gallbladder-qi;
the compound essential oil of example 5 is used for patients with mild and moderate insomnia with heart-kidney imbalance; the compound essential oil of example 6 is used for the patients with severe insomnia caused by imbalance between heart and kidney;
the compound essential oil of example 7 is used by patients with mild and moderate insomnia caused by liver depression transforming into fire; the compound essential oil of the example 8 is used by the patients with severe insomnia caused by liver depression transforming into fire;
the compound essential oil of example 9 is used for patients with mild and moderate insomnia caused by phlegm-heat internal disturbance; the compound essential oil of example 10 is used for patients with severe insomnia due to internal disturbance of phlegm-heat.
The specific use method is as follows:
applying proper amount of the Chinese medicinal composition to the left atrium and abdomen, and slowly massaging with needle in a ring mode until the Chinese medicinal composition is absorbed; b. applying on the inner side of the wrist and massaging gently with temple until absorption; c. drip two drops into the palm of the hand and close to the nasal cavity, inhale and breathe deeply.
3. Criteria for therapeutic effect
And (3) curing: the sleeping time is recovered to be normal or the sleeping time at night exceeds 6h and more, the sleep is deep, and the energy is vigorous after the sleep is awakened;
the effect is shown: the sleep quality is obviously improved compared with the prior sleep quality, the sleep time is prolonged by 3 hours or more than the prior sleep time, but the total sleep time at night is not more than 6 hours;
improvement: the insomnia symptom is relieved earlier, but the sleeping time is increased by not more than 3 hours;
and (4) invalidation: the insomnia symptom is not relieved. The total effective rate is (cure + significant effect + improvement)/total number of cases is multiplied by 100%.
4. Results
After 28 days of treatment, the clinical effect results are shown in table 1, and the total effective rate is (recovery + significant effect + effective)/total number of cases is multiplied by 100%.
TABLE 1
Compound essential oil Number of examples Cure of disease Show effect Improvement of life Invalidation Total effective rate (%)
Example 1 88 35 28 24 1 98.9
Example 2 32 12 11 7 2 93.8
Example 3 82 26 32 22 2 97.6
Example 4 38 10 16 9 3 92.1
Example 5 73 15 36 21 1 98.6
Example 6 47 12 18 13 4 91.5
Example 7 78 20 38 18 2 97.4
Example 8 42 11 15 13 3 92.9
Example 9 70 23 29 17 1 98.6
Example 10 50 17 20 10 3 94
The results show that: the traditional Chinese medicine composition has a remarkable improvement effect on insomnia caused by deficiency of heart and spleen, deficiency of heart and gallbladder qi, disharmony between heart and kidney, liver depression transforming into fire and phlegm heat internal disturbance, can improve the sleep quality of patients, and is worthy of clinical popularization and application.
And (3) safety evaluation: no adverse reactions or accidents occurred in all patients throughout the study.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (6)

1. The compound essential oil for treating heart-spleen deficiency type insomnia is characterized by being prepared by compounding plant essential oil and base oil, and comprises, by weight, 0.5-1% of marjoram essential oil, 0.5-1% of sweet orange essential oil, 0.5-1% of Roman chamomile essential oil, 1-1.5% of orange flower essential oil, 1.5-2% of eye-catching lavender essential oil, 2-2.5% of bitter orange leaf essential oil, 2-2.5% of pine essential oil and the balance of base oil.
2. The compound essential oil is characterized by being prepared by compounding plant essential oil and base oil, and comprises, by weight, 2-2.5% of magnolia alba leaf essential oil, 1-1.5% of rosewort essential oil, 0.5-1% of rosewood essential oil, 0.5-1% of tangerine essential oil, 2-2.5% of lime essential oil, 1-1.5% of valerian essential oil, 1-1.5% of ginger essential oil and the balance of base oil.
3. The compound essential oil for treating heart-kidney imbalance type insomnia is characterized by being prepared by compounding plant essential oil and base oil, and comprises, by weight, 2-2.5% of Roman chamomile essential oil, 1-1.5% of real lavender essential oil, 2-2.5% of tuberose essential oil, 1-1.5% of pink lotus essential oil, 0.5-1% of cypress essential oil, 1-1.5% of melissa essential oil, 0.5-1% of ginger essential oil and the balance of base oil.
4. The compound essential oil is characterized by being prepared by compounding plant essential oil and base oil, and comprises, by weight, 0.5-1% of marjoram essential oil, 0.5-1% of vetiver essential oil, 1-1.5% of tangerine essential oil, 1-1.5% of spikenard essential oil, 2-2.5% of melissa essential oil, 2-2.5% of bergamot essential oil, 1-1.5% of german blue chamomile essential oil and the balance of base oil.
5. The compound essential oil for treating phlegm-heat internal disturbance type insomnia is characterized by being prepared by compounding plant essential oil and base oil, and comprises 2-2.5% of tangerine essential oil, 1-1.5% of sanshool essential oil, 2-2.5% of eucalyptol and rosemary essential oil, 1-1.5% of gardenia essential oil, 1-1.5% of ginger essential oil, 1-1.5% of valerian essential oil and the balance of base oil in percentage by weight.
6. The compound essential oil according to any one of claims 1 to 5, wherein the base oil is selected from one or more of wheat germ oil, jojoba oil, avocado oil, sweet almond oil and grape seed oil.
CN202011016359.XA 2020-09-24 2020-09-24 Compound essential oil for treating insomnia Pending CN112168885A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011016359.XA CN112168885A (en) 2020-09-24 2020-09-24 Compound essential oil for treating insomnia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011016359.XA CN112168885A (en) 2020-09-24 2020-09-24 Compound essential oil for treating insomnia

Publications (1)

Publication Number Publication Date
CN112168885A true CN112168885A (en) 2021-01-05

Family

ID=73955458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011016359.XA Pending CN112168885A (en) 2020-09-24 2020-09-24 Compound essential oil for treating insomnia

Country Status (1)

Country Link
CN (1) CN112168885A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113509528A (en) * 2021-04-23 2021-10-19 花安堂生物科技集团有限公司 Composition and sleep-aiding product containing magnolia sieboldii extract
CN114796333A (en) * 2022-05-05 2022-07-29 重庆聿安生物科技有限公司 Sleep-aiding traditional Chinese medicine essential oil and blending device thereof
WO2023136151A1 (en) * 2022-01-17 2023-07-20 株式会社 資生堂 Asmt gene expression promoter

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103263596A (en) * 2013-05-21 2013-08-28 赵丽 Compound essential oil for treating insomnia
CN103479766A (en) * 2013-09-09 2014-01-01 侯根香 Compound essential oil for relieving aloneness
CN109602805A (en) * 2019-01-15 2019-04-12 深圳市淳睿贸易有限公司 Passive sleeping composition and its application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103263596A (en) * 2013-05-21 2013-08-28 赵丽 Compound essential oil for treating insomnia
CN103479766A (en) * 2013-09-09 2014-01-01 侯根香 Compound essential oil for relieving aloneness
CN109602805A (en) * 2019-01-15 2019-04-12 深圳市淳睿贸易有限公司 Passive sleeping composition and its application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
国产非特殊用途化妆品备案信息服务平台: "《http://ftba.nmpa.gov.cn:8181/ftban/itownet/hzp_ba/fw/pz.jsp?processid=201909111751152s6r5&nid=201909111751152s6r5》" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113509528A (en) * 2021-04-23 2021-10-19 花安堂生物科技集团有限公司 Composition and sleep-aiding product containing magnolia sieboldii extract
WO2023136151A1 (en) * 2022-01-17 2023-07-20 株式会社 資生堂 Asmt gene expression promoter
CN114796333A (en) * 2022-05-05 2022-07-29 重庆聿安生物科技有限公司 Sleep-aiding traditional Chinese medicine essential oil and blending device thereof

Similar Documents

Publication Publication Date Title
CN112168885A (en) Compound essential oil for treating insomnia
CN101874891B (en) Chinese medicinal composition for treating heart-throb and preparation method thereof
CN105902854A (en) Compound essential oil with tranquilizing and sleep-helping effects
CN107412589A (en) A kind of multifunction sleeping-aid mind-tranquilizing brain-strengthening pack
CN112190638A (en) Traditional Chinese medicine composition for treating insomnia after stroke in cerebral infarction recovery period and application thereof
CN110604783A (en) Traditional Chinese medicine composition beverage for treating insomnia and preparation method thereof
CN109646526A (en) A kind of Chinese medicine composition and preparation method thereof for treating depression
CN102908396B (en) Chinese medicinal composition for promoting sleeping and preparation method thereof
CN102698091B (en) Traditional Chinese medicine oral liquid for relieving neurasthenia and preparation method
CN114288235A (en) Traditional Chinese medicine composition for moxibustion and preparation method and application thereof
CN108743832B (en) Depression-relieving nerve-soothing pillow inner
CN112021696A (en) Medical mask of traditional Chinese medicine aromatherapy essential oil compound for improving sleep
CN111068023A (en) Traditional Chinese medicine composition for refreshing and application thereof
CN108042658A (en) A kind of valerian seedling medicine sleep essential oil composition and its preparation method and application
CN110448608A (en) A kind of volatile oil of middle severe pain caused by cancer of releiving and application
CN110801487A (en) Traditional Chinese medicine composition for relieving allergic rhinitis and preparation method thereof
CN113521185B (en) Traditional Chinese medicine sachet capable of relieving emotion as well as preparation method and application of traditional Chinese medicine sachet
CN114306548B (en) Traditional Chinese medicine composition for treating insomnia and application thereof
CN114209784B (en) Traditional Chinese medicine nerve-regulating composition and sachet for assisting sleep based on aromatherapy
CN116726131B (en) Essential oil composition for dizziness and application thereof
CN115350260B (en) Daily care biological agent with sleep-aiding function for skin and preparation method thereof
CN112089782B (en) Traditional Chinese medicine pillow capable of relieving depression and application thereof
CN105796946A (en) Chinese herbal preparation for treating insomnia
Somasundaram et al. Psychiatry in Siddha (Tamil) system of medicine
CN111265614A (en) Depression-relieving nerve-soothing incense and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210105

RJ01 Rejection of invention patent application after publication